1 / 48

High-Intensity Focused Ultrasound for Hepatocellular Carcinoma

High-Intensity Focused Ultrasound for Hepatocellular Carcinoma. Joint Hospital Surgical Grand Round Queen Mary Hospital 19/10/2013. Background. How HIFU works Indications / Contraindications Complications Current results. Hepatocellular carcinoma. Most common primary liver cancer

jaime-merrill
Télécharger la présentation

High-Intensity Focused Ultrasound for Hepatocellular Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. High-Intensity Focused Ultrasound for Hepatocellular Carcinoma Joint Hospital Surgical Grand Round Queen Mary Hospital 19/10/2013

  2. Background How HIFU works Indications / Contraindications Complications Current results

  3. Hepatocellular carcinoma • Most common primary liver cancer • Only 15% resectable disease on presentation • Inadequate liver function • Multifocality • Local ablative therapies for unresectable disease

  4. Local ablative therapy • Radiofrequency ablation • Ethanol injection • Microwave ablation • High-intensity focused ultrasound

  5. Background How HIFU works Indications / Contraindications Complications Current results

  6. High-Intensity Focused Ultrasound • Focused ultrasound energy (0.8MHz) from distant transducer • Hyperthermia • Coagulative necrosis • Intact tissues in between

  7. Animal studies in 1940s • Intended for treatment of Parkinson disease

  8. Current clinical applications 1990s: Transrectal HIFU for prostate cancer 2000s: MRI guided HIFU for uterine fibroid Under investigation: Pancreatic tumour, bone tumours etc.

  9. Ultrasound guided HIFU system

  10. Ultrasound guided HIFU system Therapeutic ultrasound transducer Water tank Diagnostic ultrasound probe

  11. Procedure • General anaesthesia • Immobilization • Interval cessation of ventilation • Prone / right lateral position

  12. Procedure • Planning with diagnostic ultrasound • Slice-by-slice ablation from deep to superficial region

  13. Grayscale change Before ablation After ablation

  14. Advantages / disadvantages • Advantages • No internal bleeding • No needle tract seeding • Less liver derangement • Disadvantages • Needs general anaesthesia • Lengthened procedure

  15. Background How HIFU works Indications / contraindications Complications Current results

  16. Indications • Small tumour • Less than 3cm: ablation rate >85% • Centrally located / liver dome tumour • Adjacent to major bile duct / veins • Child’s C liver function • Gross ascites Cheung TT et al. HPB 2013

  17. Liver dome tumour

  18. Liver dome tumour

  19. Tumour adjacent to major vein

  20. Tumour adjacent to major vein

  21. Indications • Small tumour • Less than 3cm: ablation rate >85% • Centrally located / liver dome tumour • Adjacent to major bile duct / veins • Child’s C liver function • Gross ascites

  22. Gross ascites

  23. Contraindications • Not fit for general anaesthesia • Cannot assume treatment position • Very poor liver function • Lesion not visualized by USG • Overlying hollow viscus • Deep tumour • Tumour close to overlying rib

  24. Deep tumour

  25. Tumour close to rib Pre-ablation Post-ablation

  26. Background How HIFU works Indications / Contraindications Complications Current results

  27. Complications (10-20%) Skin burn Bruising • Pneumothorax • Incomplete ablation (10% for small tumours)

  28. Background How HIFU works Indications / Contraindications Complications Current results

  29. Unresectable HCC (n=49) • Child’s A (n=41) and B (n=8) cirrhosis • Median size 2.2cm (0.9-8cm) Ng KK et al. Annals of Surgery 2011

  30. Unresectable HCC • Ablation rate 79.5% (n=39) • Risk factor: median tumour size (2.3cm vs. 3.8cm; p=0.03) Ng KK et al. Annals of Surgery 2011

  31. HIFU v.s. RFA Small HCC

  32. Small (<3cm) unresectable HCC (n=106) • Percutaneous RFA if feasible (n=59) • HIFU (n=47) if • Technically difficult percutaneous RFA • Liver dome tumour • Ascites • Child’s B cirrhosis Cheung TT et al. HPB 2013

  33. HIFU vs. RFA Cheung TT et al. HPB 2013

  34. Survival 81% 80% 34% 26% Cheung TT et al. HPB 2013

  35. Tumours close to pedicles

  36. Liver tumours (n=30) and pancreatic tumours (n=6) • Tumour <1cm from • IVC / hepatic /portal veins (n=27) • Bile ducts (n=4) • 1 portal vein thrombosis (Pancreatic cancer) • No bile duct injury Franco O et al. AJR 2013; 195

  37. HCC (n=39) with close proximity to major veins • No venous thrombosis / bile duct injury Zhang L et al. Eur Radiol 2008

  38. Special condition Locally advanced HCC

  39. Locally advanced (4-14cm, mean 10.5cm) HCC (n=50) • Randomized controlled trial • TACE + HIFU (n=24) • TACE only (n=26) Wu F et al. Radiology 2005

  40. TACE + HIFU vs. TACE Wu F et al. Radiology 2005

  41. Survival TACE + HIFU TACE only Wu F et al. Radiology 2005

  42. Locally advanced HCC • Combined HIFU / TACE is a promising approach • On-going trial in QMH Wu F et al. Radiology 2005

  43. Special condition Bridging to transplant

  44. Retrospective study • Transplant candidates for HCC (n=49) • Bridging HIFU (n=5) • Bridging TACE (n=29) • No bridging therapy (n=15) • Non-transplant candidates with HIFU (n=5) Cheung TT et al. WJG 2013

  45. Bridging to transplant Cheung TT et al. WJG 2013

  46. Bridging to transplant • 3 patients in HIFU group received liver transplant • Pathology • Complete necrosis (n=2) • 90% necrosis (n=1) Cheung TT et al. WJG 2013

  47. Liver transplant candidate • Effective bridging therapy to liver transplant Cheung TT et al. WJG 2013

  48. Summary • Current applications • Ablative therapy for small unresectable HCC • Child’s C liver function • Tumour close to major pedicle • Combined with TACE for large HCC • Bridging therapy to liver transplantation • Under investigation • More clinical studies warranted

More Related